BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3029 related articles for article (PubMed ID: 1532677)

  • 1. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
    Hu XT; Wachtel SR; Galloway MP; White FJ
    J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
    Hu XT; Brooderson RJ; White FJ
    Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus.
    Carlson JH; Bergstrom DA; Demo SD; Walters JR
    Synapse; 1990; 5(2):83-93. PubMed ID: 2309160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
    Jiang LH; Kasser RJ; Altar CA; Wang RY
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontogeny of nigrostriatal dopamine neuron autoreceptors: iontophoretic studies.
    Wang L; Pitts DK
    J Pharmacol Exp Ther; 1995 Jan; 272(1):164-76. PubMed ID: 7815330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    Synapse; 1988; 2(4):416-23. PubMed ID: 2973142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model.
    Lawler CP; Gilmore JH; Watts VJ; Walker QD; Southerland SB; Cook LL; Mathis CA; Mailman RB
    Synapse; 1995 Dec; 21(4):299-311. PubMed ID: 8869160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE; Wooten GF
    Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellularly recorded response of rat striatal neurons in vitro to fenoldopam and SKF 38393 following lesions of midbrain dopamine cells.
    Twery MJ; Thompson LA; Walters JR
    Synapse; 1994 Sep; 18(1):67-78. PubMed ID: 7825125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 152.